Since TGF-β downregulates ASCL1 through the SMAD pathway, EZH2 promotes SCLC progression by blocking the TGF-β-SMAD-ASCL1 axis, suggesting that reducing EZH2 expression indirectly lowers ASCL1 levels (85). The gene discussed is EZH2; the disease is small cell lung carcinoma.